Equites Radar

TEVA · Teva Pharmaceutical Industries

Drug Manufacturers - Specialty & GenericIsraelAnalyst view: Strong Buy

$31.18

+3.42% last session

End-of-day data · updated 2026-07-25

Neutral2 bullish · 2 bearish technical signals
Consensus: Strong Buy (1.42 from 10 analysts)
To mean target: +31.2%

Market cap

$36B

Enterprise value

$49B

Trailing P/E

23.0

Forward P/E

10.0

Dividend yield

Beta

0.86

Avg volume

6M

Employees

31K

2D change

-1.19%

5D change

-0.61%

10D change

-2.38%

30D change

-8.36%

60D change

-10.98%

MTD change

-7.86%

YTD change

-1.28%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.42
Covering analysts10
Mean price target$40.90
Low price target$33.00
Upside to mean target+31.2%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)41.9
50-day MA$33.52
200-day MA$30.32
Price vs 50-day MA-7.0%
Price vs 200-day MA+2.8%
MACD histogram-0.23
Volume vs 3-month avg0.7×
52w low $15.3852w high $36.34

Analyst sentiment over time — TEVA

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-28

Latest call per bank · past 12 months

Barclays

Overweight

$40.00

+28.3% vs price
▲ raised from $38.00Maintains · 2026-05-06

JP Morgan

Overweight

$40.00

+28.3% vs price
▲ raised from $35.00Maintains · 2026-04-30

UBS

Buy

$42.00

+34.7% vs price
▲ raised from $36.00Maintains · 2026-04-30

Bank of America

Buy

$42.00

+34.7% vs price
▲ raised from $38.00Maintains · 2026-04-09

Goldman Sachs

Buy

$45.00

+44.3% vs price
▲ raised from $36.00Maintains · 2026-02-09

Jefferies

Buy

$40.00

+28.3% vs price
▲ raised from $29.00Maintains · 2026-01-06

Recent rating actions

DateFirmActionRatingPrice target
2026-07-28Piper SandlerMaintainsOverweight$42.00 $44.00
2026-05-06BarclaysMaintainsOverweight$38.00 $40.00
2026-04-30JP MorganMaintainsOverweight$35.00 $40.00
2026-04-30UBSMaintainsBuy$36.00 $42.00
2026-04-30Piper SandlerReiteratesOverweight$41.00 $42.00
2026-04-30Truist SecuritiesMaintainsBuy$42.00 $45.00
2026-04-09Bank of AmericaMaintainsBuy$38.00 $42.00
2026-03-04Piper SandlerReiteratesOverweight$40.00 $41.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-23

  • RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 7.0% below the 50-day MA ($33.52).
  • Price vs 200-day MA: Trading 2.8% above the 200-day MA ($30.32).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.23) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($15.38) and high ($36.34).

TEVA Price Chart

Loading chart for TEVA

Fundamentals

Revenue (TTM)$17B
EBITDA$5.0B
Free cash flow$3.0B
Operating cash flow$2.0B
Book value / share$7.07
Net debt / EBITDA2.6
WACC9.0%
Revenue growth2.00%
Earnings growth72.00%

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

More in Drug Manufacturers - Specialty & Generic

Screen TEVA against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.